literature

HIV mutation literature information.

Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.

PMID: 35511892 2022 American journal of health-system pharmacy

Abstract: At the time of regimen change (HD 67), a resistance panel showed minor mutations, E157Q and V118I.

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.

PMID: 34694877 2022 Antimicrobial agents and chemotherapy

Table: E157Q

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Abstract: The on-study secondary integrase substitution E157Q or L74I was observed in 2 participants.

Result: In 2 participants, a single INSTI-associated polymorphic substitution of E157Q or L74I (n = 1 each) was identified during the study, but given that no pretreatment samples from either participant were available for integrase assessment, it was not possible to determine if emergence had occurred during the study period.

Table: E157Q

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: E157K/Q

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.

PMID: 35300056 2022 Pharmacogenomics and personalized medicine

Result: A total of 12 polymorphic accessory mutations were detected, including E157Q (0.58%, 5/865), T97A (0.23%, 2/865), E138A (0.12%, 1/865), E157EQ (0.12%, 1/865), G163R (0.12%, 1 /865), Q95K (0.12%, 1/865), and S230R (0.12%, 1/865) (as shown in Figure 2).

Table: E157Q

Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.

PMID: 35458459 2022 Viruses

Result: A total of 4.4% (20/460) of the sequences contained five different IN accessory mutations: -E157Q (2.39%), G163R/K (0.65%), Q95K (0.65%), T97A (0.43%), and G149A (0.22%).

Result: Among the INSTI-mutation positions in the CCD residues that directly reduced the INTSI susceptibility, H51, T66, E92, F121, G140, Y143, Q146, S147, Q148, S153, N155, and E157Q were highly conserved, except for codon position E157Q, which was a polymorphic position (>1.0% variability).

Result: Only one accessory mutation per sequence was detected, except for one sequence with two (G149A and E157Q) accessory m

Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.

PMID: 35240975 2022 Current HIV research

Abstract: Additional mutations, E92Q, E138K, G140A, S147G, and Q148R were found in elvitegravir; E192Q, E138K/T, G140A/S, S147G, Q148H/R, N155H, E157Q were found in dolutegravir (DTG) experienced patients.

Abstract: Major INSTI-mutations E138K, Y143R, S147G, Q148R, N155H, and E157Q were found in raltegrav

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.

PMID: 33807382 2021 Viruses

Abstract: Individuals with 4-class DRMs plus integrase T97 and E157Q mutations appear to have worse outcomes.

Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).

PMID: 34279816 2021 Infection

Abstract: The most common major resistance mutation was E138AK (0.5%, 5/999), while the most common accessory resistance mutation was E157Q (1.8%, 18/999).

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.

PMID: 33892628 2021 BMC infectious diseases

Abstract: CONCLUSIONS: Our analysis indicated that all RAM's that resulted in a change in the number of interactions with encompassing residues does not affect DTG binding, while accessory mutations E157Q and D232N could affect DTG binding leading to possible DTG resistance.

Abstract: Except for accessory mutant structure E157Q, only one MG contact was made with DTG, while DTG had no MG ion contacts and no DDE motif residue contacts for structure D232N.

Abstract: Of these,11.8% (34/287) of the sequences contained five different IN accessory mutations; namely Q95K, T97A, G149A, E157Q and D232N.

Browser Board

Co-occurred Entities

Filtrator